These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7485301)

  • 1. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results.
    Bahado-Singh RO; Goldstein I; Uerpairojkit B; Copel JA; Mahoney MJ; Baumgarten A
    Am J Obstet Gynecol; 1995 Oct; 173(4):1106-10. PubMed ID: 7485301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome.
    Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A
    Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comprehensive midtrimester test: high-sensitivity Down syndrome test.
    Bahado-Singh R; Shahabi S; Karaca M; Mahoney MJ; Cole L; Oz UA
    Am J Obstet Gynecol; 2002 Apr; 186(4):803-8. PubMed ID: 11967511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-sensitivity alternative to "routine" genetic amniocentesis: multiple urinary analytes, nuchal thickness, and age.
    Bahado-Singh R; Oz U; Kovanci E; Cermik D; Copel J; Mahoney MJ; Cole L
    Am J Obstet Gynecol; 1999 Jan; 180(1 Pt 1):169-73. PubMed ID: 9914599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuchal thickness, urine beta-core fragment level, and maternal age for down syndrome screening.
    Bahado-Singh RO; Oz AU; Flores D; Cermik D; Acuna E; Mahoney MJ; Cole L
    Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 1):491-5. PubMed ID: 9988824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies.
    Bahado-Singh RO; Oz U; Shahabi S; Mahoney MJ; Baumgarten A; Cole LA
    Am J Obstet Gynecol; 2000 Nov; 183(5):1114-8. PubMed ID: 11084551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical appraisal of the use of nuchal fold thickness measurements for the prediction of Down syndrome.
    Locatelli A; Piccoli MG; Vergani P; Mariani E; Ghidini A; Mariani S; Pezzullo JC
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):192-7. PubMed ID: 10649178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
    Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
    Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers.
    Nyberg DA; Luthy DA; Cheng EY; Sheley RC; Resta RG; Williams MA
    Am J Obstet Gynecol; 1995 Oct; 173(4):1030-5. PubMed ID: 7485289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
    Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH
    Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age.
    Bahado-Singh RO; Oz AU; Kovanci E; Deren O; Copel J; Baumgarten A; Mahoney J
    Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1627-31. PubMed ID: 9855608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.
    Burton BK; Prins GS; Verp MS
    Am J Obstet Gynecol; 1993 Sep; 169(3):526-30. PubMed ID: 7690522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prenatal diagnosis of trisomy 21 in monozygotic twins with increased nuchal translucency and abnormal serum biochemistry.
    Verdin SM; Braithwaite JM; Spencer K; Economides DL
    Fetal Diagn Ther; 1997; 12(3):153-5. PubMed ID: 9313073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.
    Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A
    Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ; Watt HC; Hackshaw AK
    N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
    Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined second-trimester biochemical and ultrasound screening for Down syndrome.
    Benn PA; Kaminsky LM; Ying J; Borgida AF; Egan JF
    Obstet Gynecol; 2002 Dec; 100(6):1168-76. PubMed ID: 12468159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple screening for fetal Down's syndrome with the classic triple test, dimeric inhibin A and ultrasound.
    Debiève F; Bouckaert A; Hubinont C; Thomas K
    Gynecol Obstet Invest; 2000; 49(4):221-6. PubMed ID: 10828702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.